JWH-073

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-09-07srcMonitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds
4. 2026-09-07srcToxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1
5. 2026-09-07srcAdverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal
6. 2026-09-07srcCardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation
7. 2026-09-07srcMonohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
8. 2026-09-07srcMonitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases
9. 2026-09-07srcInfluence of structural characteristics on the binding of synthetic cannabinoids from the JWH family to the CB1 receptor: A computational study
10. 2026-09-07srcMoving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids
11. 2026-09-07srcMethodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073
12. 2026-09-07srcEffect of JWH-250, JWH-073 and their interaction on tetrad, sensorimotor, neurological and neurochemical responses in mice
13. 2026-09-07srcHuman metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors
14. 2026-09-07srcA sensitive GC-EIMS method for simultaneous detection and quantification of JWH-018 and JWH-073 carboxylic acid and hydroxy metabolites in urine
15. 2026-09-07srcDetection Times of Carboxylic Acid Metabolites of the Synthetic Cannabinoids JWH-018 and JWH-073 in Human Urine
16. 2026-09-07srcSensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice
17. 2026-09-07srcK2 toxicity: fatal case of psychiatric complications following AM2201 exposure
18. 2026-09-07srcAcute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings
19. 2026-09-07src"Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans
20. 2026-09-07srcConjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases
21. 2026-09-07srcDifferential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy
22. 2026-09-07srcThe adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects
23. 2026-09-07srcThree cases of spice exposure
24. 2026-09-07srcA systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
25. 2026-09-07srcBehavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Delta9-THC in Rats
26. 2026-09-07srcSynthetic cannabinoid JWH-073 alters both acute behavior and in vivo/vitro electrophysiological responses in mice
27. 2026-09-07srcQSAR Model for Predicting the Cannabinoid Receptor 1 Binding Affinity and Dependence Potential of Synthetic Cannabinoids
28. 2026-09-07srcSynthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high
29. 2026-09-07srcStructure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors
30. 2026-09-07srcStratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice
31. 2026-09-07srcKi binding affinity values for JWH-073 at CB1 (8.9 nM) and CB2 (38 nM) receptors
32. 2026-09-07srcDEA Temporary Scheduling of Five Synthetic Cannabinoids Including JWH-073
33. 2026-09-07srcPermanent Scheduling of Five Synthetic Cannabinoids Including JWH-073
34. 2026-09-07srcJWH-073 SMILES and Chemical Structure
35. 2026-09-07srcJWH-073 Discovery - John W. Huffman, Clemson University
36. 2026-09-04issueIssued emergency
37. 2026-09-04issueIssued info_card
38. 2026-09-04issueIssued notice
39. 2026-06-04proposal27 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
40. 2026-06-04publicationPublication — backfill
41. 2026-05-11revisionRevision 1
42. 2026-05-11absenceSearched ClinicalTrials.gov for "JWH-073 synthetic cannabinoid" — no results
43. 2026-05-11genGeneration — pipeline-v5 · with 3 morepipeline-v5
44. 2026-05-11rungeneration run

The same entries, as forms: six forms.